J
Joao Victor Machado Alessi
Researcher at Harvard University
Publications - 67
Citations - 574
Joao Victor Machado Alessi is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 22 publications receiving 134 citations. Previous affiliations of Joao Victor Machado Alessi include Adma & University of São Paulo.
Papers
More filters
Acquired resistance to pd-(l)1 blockade in patients with non-small cell lung cancer
Biagio Ricciuti,Giuseppe Lamberti,Joao Victor Machado Alessi,Federica Pecci,Alessandro,Di Gennaro Federico,Xinan Wang,Adriana Barrichello,V. Vaz,A. Pangilinan,Danielle Haradon,Lee Elinton,Mizuki Nishino,Scott J. Rodig,Lynette M. Sholl,Mark M. Awad +15 more
TL;DR: In this article , the authors compared pre and post PD-(L)1 blockade, chemotherapy (control cohort #1) and targeted therapy (EGFR inhibitors, control cohort #2) tumor biopsies.
Journal ArticleDOI
Letter to the Editor: Reply to Zhao, Wu, and Ma.
TL;DR: Zhao et al. as discussed by the authors identified that better patient performance status, low derived neutrophil-to-lymphocyte ratio in the blood, increasing programmed death-ligand 1 expression, and STK11/KEAP1/SMARCA4 wild-type status are associated with improved clinical outcomes to first-line chemoimmunotherapy (CIT) in NSCLC.
Journal ArticleDOI
Abstract 4117: Clinicopathologic and molecular characterization of KRASG12D lung cancers
Jia Luo,Biagio Ricciuti,Joao Victor Machado Alessi,Xinan Wang,V. Vaz,Federica Pecci,Tom C. Nguyen,James Lindsay,Bijaya Sharma,Kristen Felt,Scott J. Rodig,Mizuki Nishino,Lynette M. Sholl,David A. Barbie,Pasi A. Jänne,Mark M. Awad +15 more
TL;DR: Patients with advanced KRASmut NSCLC and adequate baseline tissue for multiplex-immunofluorescence harbored KRASG12D, which had lower PD-L1 tumor proportion score (TPS) and lower tumor mutation burden (TMB) compared to patients with KRASnon-G 12D,high-sm, and there was no difference in clinical outcomes to chemo-IMmunotherapy.
Proceedings ArticleDOI
512 Time-of-day of pembrolizumab infusion and clinical outcomes of patients with NSCLC: too soon to promote morning infusions
Alessio Cortellini,Adriana Barrichello,Joao Victor Machado Alessi,Biagio Ricciuti,Victor Vatz,Thomas Newsom-Davis,Joanne Evans,Giuseppe Lamberti,Federica Pecci,P. Viola,Antonio D'Alessio,Claudia Angela Maria Fulgenzi,Mark M. Awad,David J. Pinato +13 more
TL;DR: In this paper , the authors evaluated the association between time-of-day patterns of pembrolizumab infusion and outcomes in a cohort of patients with treatment-naïve metastatic lung cancer with PD-L1 expression.
Journal ArticleDOI
Abstract 2143: Clinicopathologic, genomic and immunophenotypic landscape of ATM mutations in non-small cell lung cancer
Biagio Ricciuti,Joao Victor Machado Alessi,Xinan Wang,Arrien A. Bertram,V. Vaz,Mizuki Nishino,James Lindsay,Kristen Felt,Bijaya Sharma,Lynette M. Sholl,Rodig Scott,Mark M. Awad,Michael L. Cheng +12 more
TL;DR: Deleterious ATM mutations defined a subset of NSCLC with unique clinicopathologic, genomic, and immunophenotypic features and had similar outcomes to PD-(L)1 inhibition +/- chemotherapy, compared to ATMWT cases, and similar immune cell subsets infiltration.